MiniMed Group, Inc. — fact timeline

Linnea Burman was appointed as Class II Director at MiniMed Group, Inc..

“On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.”

David Endicott was appointed as Class I Director at MiniMed Group, Inc..

“On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.”

MiniMed Group, Inc. reported financial results for fourth quarter and full fiscal year ended April 24, 2026.

“On June 3, 2026, MiniMed Group, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results and related information for its fourth quarter and full fiscal year 2026.”

Scott Cundy was appointed as Director at MiniMed Group, Inc..

“On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure.”

Brett Wall resigned as Director at MiniMed Group, Inc..

“On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026.”

MiniMed Group, Inc.: Amended and restated its bylaws (effective 2026-03-06).

“On March 6, 2026, the Company amended and restated its bylaws (as so amended and restated, the “ Bylaws ”).”

MiniMed Group, Inc.: Amended and restated its certificate of incorporation (effective 2026-03-06).

“On March 6, 2026, the Company amended and restated its certificate of incorporation (as so amended and restated, the “ Certificate of Incorporation ”).”

MiniMed Group, Inc. incurred revolving credit of $500 million with Citibank, N.A. maturing five years.

“On January 15, 2026, KH2 entered into a credit agreement which provides for a five-year senior secured revolving credit facility (the “ Revolving Credit Facility ”) in an aggregate principal amount of $500 million to be made available in U.S. dollars and certain approved alternative currencies, initially including Euros, with Citibank, N.A. serving as administrative agent for a syndicate of lenders.”

MiniMed Group, Inc. entered into Transition Services Agreement with Medtronic plc.

“• Transition Services Agreement, pursuant to which Medtronic provides to the Company and the Company provides to Medtronic certain services for a limited period of time following the completion of the Separation.”

MiniMed Group, Inc. entered into Registration Rights Agreement with Medtronic plc.

“• Registration Rights Agreement, pursuant to which the Company has granted Medtronic certain registration rights with respect to the shares of Common Stock owned by Medtronic following the completion of the IPO.”

MiniMed Group, Inc. entered into Tax Matters Agreement with Medtronic plc.

“• Tax Matters Agreement, which governs the Company and Medtronic’s respective rights, responsibilities, and obligations with respect to tax matters, including tax liabilities (including responsibility and potential indemnification obligations for taxes attributable to the Company’s business and taxes arising, under certain circumstances, in connection with the Separation and the Divestment, if pursued), tax attributes, tax contests, and tax returns.”

MiniMed Group, Inc. entered into merger agreement with Kangaroo US HoldCo 2, Inc. (effective 2026-03-05).

“On March 5, 2026, the Company entered into a merger agreement with KH2 and KH2 merged with and into the Company, with the Company surviving the merger.”

MiniMed Group, Inc. entered into Separation Agreement with Medtronic plc.

“• Separation Agreement, which sets forth the Company’s agreements with Medtronic regarding the principal actions to be taken in connection with the Separation and governs, among other matters, (1) the allocation of assets and liabilities to the Company and Medtronic (including the Company’s indemnification obligations, for potentially uncapped amounts, for certain liabilities relating to the Company’s business activities, whether incurred prior to or following the completion of the IPO) and (2) certain matters with respect to the IPO and Medtronic’s intended tax-free distribution to its shareholders of all or a portion of its remaining equity interest in the Company (such distribution, the “ Divestment ”).”

MiniMed Group, Inc. completed a disposition involving MiniMed Group, Inc..

“The description of the Company’s merger with KH2 set forth under Item 1.01 above is incorporated herein by reference.”